{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04649216: Phase 1 Interventional Completed Healthy Volunteers
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Chugai Pharmaceutical is developing a parathyroid 1 receptor agonist called as PCO371. It is known that parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor. PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism. This drug participated in phase I clinical trial in healthy volunteers. However, Chugai Pharmaceutical has terminated this study. No recent reports of the development of PCO371are available.
Status:
Investigational
Source:
NCT02886065: Phase 1 Interventional Active, not recruiting Smoldering Multiple Myeloma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
HDAC-IN-2 (also known as citarinostat or ACY-241) was developed as a selective histone deacetylase (HDAC) 6 inhibitor with potential antineoplastic activity. Inhibition of HDAC leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC-IN-2 participates in phase 1b clinical trial in patients with multiple myeloma to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity. Besides, HDAC-IN-2 in combination with paclitaxel participates in phase Ib in patients with advanced solid tumors. In addition, HDAC-IN-2 in combination with nivolumab participates in phase I in patients with unresectable non-small cell lung cancer to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of the drug.
Status:
Investigational
Source:
USAN:ULODESINE SUCCINATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Icopezil (previously known as CP-118,954) was developed as a selective acetylcholinesterase inhibitor for the treatment of cognitive disorders. Phase II trials of icopezil were underway in Japan and in the USA for the treatment of patients with Alzheimer's disease. However, Pfizer has discontinued these studies.
Status:
Investigational
Source:
NCT04692688: Phase 2 Interventional Completed Diabetic Retinopathy
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01870115: Phase 1 Interventional Completed Osteoporosis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02859857: Phase 1 Interventional Completed Neoplasms
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
1,2-Dioleoyl-sn-glycero-3-phospho-L-serine Sodium Salt is a lipid being studied in the assembly and long-term stability of solid supported lipid bilayers from artificial and natural lipid mixtures.
Status:
Investigational
Source:
NCT04566679: Not Applicable Interventional Unknown status Irritable Bowel Syndrome (IBS)
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:stibosamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Stibosamine is a Salts of p-aminophenylstibinic acid and N-ethylethanamine patented by Hynson, Westcott & Dunning for the treatment kala-azar infection.
Status:
Class (Stereo):
CHEMICAL (EPIMERIC)
Detajmium bitartrate anhydrous is Rauwolfia alkaloid. It is a sodium-channel-blocking drug with an extremely long recovery from use-dependent sodium channel block. Detajmium has antiarrhythmic properties. It caused comparable prolongations of the intraventricular conduction time during sinus rhythm and progressively broadened the QRS complex. Rauwolfia alkaloids use is restricted by serious adverse effects, such as dysrhytmias. Several detajmium bitartrate lethal intoxications were reported.
